Botox and the value of never-ending profits
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
Takeover flurry aside, progress of recent biotech floats underwhelms
A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are…
First-quarter floats hold amid uncertain climate
Biotech IPOs record another strong quarter, setting the pace for a bumper year of new issues.
